Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

FranceBack to France

Clinical trials in Caen – page 36

659 clinical trials in Caen, France across 3 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

FranceOur site in FranceEssaisCliniques.fr(opens in a new tab)
Caen at a glance
659
clinical trials
  • Research sites3
Type of trial
Recruitment status
Quick filters

659 trials in Caen

Open in trial search

Immune thrombocytopenia

Not recruiting

Study of rituximab and belimumab combination compared to rituximab alone in adults with persistent or chronic immune thrombocytopenia (ITP)

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Belimumab
  • Sponsor:Assistance Publique Hopitaux De Paris

Acute myeloid leukaemia

Not recruiting

Study of gemtuzumab ozogamicin and chemotherapy combinations in children with newly diagnosed acute myeloid leukemia, high-risk myelodysplastic syndrome, or myeloid sarcoma

Registered drugNo placebo
Countries:FranceFrance
  • Participants:0–17 years
  • Substances:Busulfan
  • Sponsor:The University Of Birmingham

Non-small cell lung cancer stage IV

Not recruiting

Study of Atezolizumab, Carboplatin, and Paclitaxel for Elderly Patients with Advanced Non-Small Cell Lung Cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:65+ years
  • Substances:Atezolizumab
  • Sponsor:Intergroupe Francophone De Cancerologie Thoracique

Plasma cell myeloma

Not recruiting

Study Comparing Lenalidomide, Daratumumab, and Dexamethasone for Frail Patients with Untreated Multiple Myeloma Not Eligible for High-Dose Therapy

Registered drugNo placebo
Countries:FranceFrance
  • Participants:65+ years
  • Substances:Daratumumab
  • Sponsor:Centre Hospitalier Universitaire De Lille

Gastrointestinal carcinoma

Not recruiting

Study on the Safety and Effectiveness of Domvanalimab, Zimberelimab, and Quemliclustat in Adults with Advanced Upper Gastrointestinal Cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Calcium Folinate
  • Sponsor:Arcus Biosciences Inc.

Juvenile psoriatic arthritis

Not recruiting

Study on Ustekinumab and Guselkumab for Children with Active Juvenile Psoriatic Arthritis

Registered drugNo placebo
Countries:FranceFrance
  • Participants:0–17 years
  • Substances:Guselkumab
  • Sponsor:Janssen Cilag International

Metastatic renal cell carcinoma

Not recruiting

Study on Pausing Treatment with Pembrolizumab and Axitinib in Patients with Metastatic Kidney Cancer at Good or Intermediate Risk

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Axitinib
  • Sponsor:Centre Hospitalier Universitaire De Bordeaux

Breast cancer+1

Not recruiting

Study of Tucatinib and Ado-Trastuzumab Emtansine for Patients with Advanced HER2+ Breast Cancer

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Tucatinib
  • Sponsor:Seagen Inc.

Acute graft versus host disease in intestine

Not recruiting

Study on MaaT013 for Treating Acute Gastrointestinal Graft-Versus-Host Disease in Patients Not Responding to Ruxolitinib

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Allogeneic Faecal Microbiota, Pooled
  • Sponsor:Maat Pharma

Plasma cell myeloma

Not recruiting

Study of Teclistamab with Daratumumab or Lenalidomide for Elderly Patients with Newly Diagnosed Multiple Myeloma

Registered drugNo placebo
Countries:FranceFrance
  • Participants:65+ years
  • Substances:Daratumumab
  • Sponsor:Centre Hospitalier Universitaire De Lille

Myelofibrosis

Not recruiting

Study on Treosulfan, Fludarabine Phosphate, and Thiotepa for Patients with Myelofibrosis Undergoing Haplo-identical Transplantation

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Thiotepa
  • Sponsor:Assistance Publique Hopitaux De Paris

Squamous cell carcinoma of head and neck

Not recruiting

Study on the Safety and Tolerance of Durvalumab and Radiotherapy for Patients with Untreated Head and Neck Squamous Cell Carcinoma

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Durvalumab
  • Sponsor:Groupe Oncologie Radiotherapie Tete Cou

Other cities in France

The busiest research cities in the country

All 382 cities in France

Clinical research in Caen

What the registry says about research in the country

01 Oncology Studies

Innovative research focusing on multiple cancer types including head and neck squamous cell carcinoma, endometrial cancer, and multiple myeloma. Studies evaluate novel therapeutic combinations and treatment strategies.

  • Advanced solid tumors
  • Hematological malignancies
  • Gastrointestinal cancers

Trials investigate targeted therapies and immunotherapy approaches for improved patient outcomes.

02 Infectious Disease Research

Studies examining prevention and treatment of respiratory infections, with focus on respiratory syncytial virus (RSV) in vulnerable populations. Investigation of novel antibiotics for prosthetic joint infections.

  • Viral infections
  • Bacterial infections
  • Preventive treatments

Research aims to develop effective preventive strategies and therapeutic interventions.

03 Cardiovascular Medicine

Research exploring treatments for heart failure prevention and management of cardiovascular conditions. Studies evaluate antiplatelet therapy strategies in elderly patients following interventional procedures.

  • Heart failure
  • Coronary interventions
  • Preventive cardiology

Focus on improving cardiovascular outcomes through innovative therapeutic approaches.

Back to FranceAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.